# reload+after+2024-01-20 00:43:44.118709
address1§200 Greenhill Road
city§Eastwood
state§SA
zip§5063
country§Australia
phone§61 8 8150 7400
website§https://www.bionomics.com.au
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Spyridon  Papapetropoulos M.D., Ph.D.', 'age': 50, 'title': 'CEO, President & Director', 'yearBorn': 1973, 'fiscalYear': 2023, 'totalPay': 517935, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Adrian  Hinton BEC, F.C.A.', 'age': 70, 'title': 'Financial Controller', 'yearBorn': 1953, 'fiscalYear': 2023, 'totalPay': 201359, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Timothy M. Cunningham CPA, M.B.A.', 'age': 60, 'title': 'Chief Financial Officer', 'yearBorn': 1963, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Prof. Paul  Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D.', 'title': 'Consultant Chief Medical Officer of Clinical Neuroscience', 'fiscalYear': 2023, 'totalPay': 68564, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Julie  Kerner Ph.D.', 'title': 'Senior Vice President of Business Operations', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Atul R. Mahableshwarkar DFAPA, M.D.', 'title': 'Acting Chief Medical Officer', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Suzanne  Irwin B.Com., FCIS', 'title': 'Company Secretary', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1703980800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§-0.234
priceToSalesTrailing12Months§16.203592
currency§USD
dateShortInterest§1702598400
forwardEps§-1.86
exchange§NGM
quoteType§EQUITY
shortName§Bionomics Limited - American De
longName§Bionomics Limited
firstTradeDateEpochUtc§1639665000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§4e477dfa-aa36-3df0-8418-7ef77e024c33
gmtOffSetMilliseconds§-18000000
targetHighPrice§10.0
targetLowPrice§8.0
targetMeanPrice§9.0
targetMedianPrice§9.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§2
quickRatio§4.575
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
